NYSE:LLYPharmaceuticals
Eli Lilly PsA Trial Links Dual Therapy Success With Valuation Upside Potential
Eli Lilly (NYSE:LLY) reported Phase 3b TOGETHER-PsA data showing that Taltz combined with Zepbound outperformed Taltz alone in adults with both active psoriatic arthritis and obesity.
The trial represents the first time a dual-targeted approach has shown efficacy in this comorbid population, linking an immunology therapy with a metabolic drug in one regimen.
The findings create a potential path toward label expansion for both medicines and may influence future treatment standards for...